IRIDEX Corporation (IRIX) insider have most recently took part in a trading activity. On Dec 12, 2017 Moore William M, Chairman and CEO bought 5,000 shares having total worth of $39,200 at the price of $7.84 per share, following the transaction a total of 83,944 shares owned by Moore William M. Before this latest buy, Moore William M purchased IRIX at 1 other times during the past twelve months, for a total investment of $16,956 at an average of $9.42 per share.
Furthermore, over the past 12 months , the stock was traded 2 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.
Shares of IRIDEX Corporation (IRIX) traded down 0.78% on Dec 14, 2017, hitting $7.62. 16,642 shares of the company’s stock traded hands. IRIDEX Corporation has a 52 week low of $7.62 and a 52 week high of $16.39. The company’s market cap is $147 million.
IRIDEX Corporation (IRIX) last announced its earnings results on Nov 2, 2017. The company reported -0.27 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.22 by $0.05. The company had revenue of $11 million for the quarter, compared to the consensus estimate of $10 million. During the same quarter in the previous year, the company posted -0.07 earnings per share. The company’s revenue for the quarter was up 11% on a year-over-year basis.
|earnings per share||-0.27||-0.24||-0.16||-0.09||-0.07||-0.03||0.01||0.04||0.04||-0.07|
Iridex Corporation was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, the company changed its name to IRIDEX Corporation and reincorporated in Delaware. It is a provider of therapeutic based laser systems and delivery devices used to treat eye diseases in ophthalmology and skin conditions in dermatology. Its ophthalmology products consist of laser systems, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases, including the three leading causes of irreversible blindness: diabetic retinopathy, glaucoma and age-related macular degeneration (“AMD”). In addition, its ophthalmology products are often used in vitrectomy procedures which are generally performed in the operating room and require a disposable single use laser probe to deliver the light to the back of the eye. Its laser systems consist of IQ products which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems; and its OcuLight products including OcuLight TX, OcuLight Symphony (Laser Delivery System), OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. The Company utilizes a systems approach to product design. Each system includes a console, which generates the laser energy, and a number of interchangeable peripheral delivery devices for use in specific clinical applications. Customers include research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics (outpatient). The Company sells and markets its products in the United States predominantly through its direct sales force and internationally through approximately 70 independent distributors into over 100 countries. The Company has issued 26 United States patents and 17 foreign patents. It is subject to extensive regulation by numerous governmental authorities, including federal, state, and foreign governmental agencies.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018